Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, Inc. (Nasdaq: AMRS) has achieved the Bonsucro Chain of Custody Certification, ensuring sustainable sugarcane supply chain practices from farmer to end user. This certification underscores Amyris' commitment to delivering clean and sustainable products in the Clean Health and Beauty sectors, aligning with ethical and fair-trade practices. CEO John Melo emphasized that consumer demand for sustainably sourced products has surged, further enhancing Amyris’ growth potential and strengthening partnerships. This makes Amyris a pioneer as the first biotech company to receive this certification, indicating significant industry differentiation.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, has completed a strategic transaction with DSM Nutritional Products Ltd valued at $50 million. This deal involves licensing rights for Farnesene to Givaudan for a specialty ingredient. Of the total amount, $30 million is due by December 30, 2020, with further payments scheduled for the first quarter of 2021 and potential milestone payments thereafter. This is the first of three anticipated transactions as per management's recent investor event on December 15, 2020.
Amyris, a synthetic biotechnology firm listed on Nasdaq as AMRS, successfully hosted the first session of its virtual investor mini-series, titled "Delivering on the Promise of Synthetic Biology." This session, held on December 15, 2020, featured nearly 300 participants and included a business update, technology presentation, and Q&A. CEO John Melo discussed strategic transactions and future outlook, while SVP Sunil Chandran showcased the company's technology platform. Future sessions are planned, focusing on the Consumer and Ingredients portfolios in Q1 2021.
Amyris, in a recent announcement, revealed the launch of a virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology". The first webinar, Science and Technology, Sustainable Solutions for a Healthier Planet, is scheduled for December 15, 2020, at 1:00 PM ET. The initiative aims to educate investors on Amyris's operations and advancements, particularly in sustainable ingredients for health and beauty markets. Future sessions will cover the Consumer and Ingredients portfolios, enhancing investor engagement.
Amyris, Inc. (Nasdaq: AMRS) reported record sales revenue from its consumer brands during Black Friday, with sales revenue tripling compared to 2019. The Biossance brand alone surpassed $1 million in sales, driven by a 129% increase in customers. Notably, 57% of sales came from first-time customers. Overall, Amyris's fourth quarter is expected to match its total sales from 2019. The company has invested in its digital infrastructure to meet rising online shopping demands, ensuring efficient supply chain and fulfillment capabilities.
Amyris, a leading synthetic biotechnology company based in Emeryville, California, will present at Evercore ISI's 3rd Annual HealthCONx Conference on December 3, 2020, at 2:40 p.m. ET. The presentation will highlight the company's innovations in sustainable and natural ingredients for Clean Health and Beauty markets. A live webcast and replay will be available on the company's Investor Relations website. Amyris is known for its three consumer brands: Biossance, Pipette, and Purecane, all built on its No Compromise promise of clean ingredients.
Amyris, Inc. (Nasdaq: AMRS) reported a strong Q3 2020, with Product Revenue reaching $31 million, up 58% year-over-year. Consumer sales surged by 203%, contributing to an expanded Gross Margin of 41%. Adjusted EBITDA improved to -$33 million, a $10 million enhancement from last year, as cash operating expenses decreased by 10% to $43 million. The company anticipates a profitable 2021, driven by successful strategic initiatives and high growth in consumer brands. However, the ongoing impact of COVID-19 adds uncertainty to the future financial outlook.
Amyris, Inc. (Nasdaq: AMRS) has partnered with Rosie Huntington-Whiteley to create a new venture, Clean Beauty Collaborative. This initiative aims to enhance Amyris' presence in the clean beauty sector, building on existing brands like Biossance and Pipette. The collaborative will develop a cosmetics line under the Rose Inc. brand, with products expected to launch in Q3 2021. Caroline Hadfield will serve as CEO, while Huntington-Whiteley will be the Chief Creative Officer. This partnership reflects Amyris' commitment to sustainable beauty innovations.
Amyris, Inc. (Nasdaq: AMRS) will announce its fiscal 2020 Q3 financial results on November 5, 2020. The earnings call is scheduled for 6:00 AM PT and will feature updates from CEO John Melo, CFO Han Kieftenbeld, and COO Eduardo Alvarez. Investors can access the call by phone or via a live webcast on the company's investor page. Amyris focuses on sustainable ingredients for health and beauty markets, utilizing advanced technologies to produce its consumer brands, including Biossance, Pipette, and Purecane.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
